Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now includes the FDA's accelerated approval of Lynozyfic™ for treating relapsed or refractory multiple myeloma, while previous information about its promising results in combination with other treatments has been removed.
    Difference
    14%
    Check dated 2025-07-04T13:23:36.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has updated its content to reflect new data on Dupixent® (dupilumab) presented at the RAD Conference, while removing information about a previous presentation at the ATS.
    Difference
    15%
    Check dated 2025-06-13T00:54:54.000Z thumbnail image
  5. Check
    30 days ago
    No Change Detected
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has added information about promising results for Linvoseltamab in combination with other treatments for Multiple Myeloma, while it has removed details about Regeneron's investor conference presentations.
    Difference
    12%
    Check dated 2025-05-29T15:29:14.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The web page has added new core content that includes updated information about pricing and stock availability for key products. Additionally, there are new time slot availability options for services offered.
    Difference
    0.3%
    Check dated 2025-05-22T11:16:30.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The web page has added a new section or content labeled 'Page 3'.
    Difference
    0.6%
    Check dated 2025-04-23T18:13:33.000Z thumbnail image
  9. Check
    95 days ago
    Change Detected
    Summary
    The page now includes the approval of Dupixent® as the first biologic medicine for COPD in Japan, while the previous announcement regarding EYLEA HD®'s positive Phase 3 results has been removed.
    Difference
    17%
    Check dated 2025-04-01T23:04:17.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.